目的 运用Meta 分析方法评价阿立哌唑治疗儿童抽动障碍(TD)的临床疗效和安全性。方法 检索2000 年1 月到2014 年8 月国内外主要数据库,收集有关阿立哌唑治疗儿童TD 的临床对照试验,将符合纳入标准的文献进行Meta 分析。结果 6 个随机对照研究(共551 个病例)纳入分析,显示在随访终点时阿立哌唑与各个传统治疗TD 的药物的疗效比较差异无统计学意义,而不同治疗时间疗效的亚组分析显示:2周、4 周和8 周时与传统治疗TD 的药物比较,差异亦无统计学意义。与氟哌啶醇比较,二者疗效无差别,但阿立哌唑的锥体外系反应较少(P<0.05),就总不良反应而言,尚不能认为阿立哌唑较传统药物具有更低的发生率。结论 与传统的药物相比,阿立哌唑在改善儿童TD 主要症状方面同样疗效显著,但尚不能认为阿立哌唑更具安全性。
Abstract
Objective To evaluate the clinical efficacy and safety of aripiprazole in the treatment of childhood tic disorders (TD) by a meta analysis. Methods A systematic search for randomized controlled trials (RCTs) on the efficacy and safety of aripiprazole in the treatment of childhood TD that were published between January 2000 and August 2014 was conducted. A Meta analysis on the selected RCTs was conducted using Review Manager 5.2 software. Results Six RCTs involving 551 TD patients were enrolled. There were no significant differences in the efficacy between aripiprazole and traditional drugs for treatment of TD either by the end of follow-up visit or at 2 weeks, 4 weeks and 8 weeks after treatment. The subgroup analysis results indicated that aripiprazole had the same efficacy for the treatment of TD as traditional drug haloperidol. Aripiprazole had a lower incidence of extrapyramidal reactions than haloperidol (P<0.05), but the overall incidence of side effects of aripiprazole was not lower than traditional drugs for treatment of TD. Conclusions The available evidence suggests that aripiprazole has the same curative effect in the treatment of childhood TD compared with the traditional drugs. However, it is difficult to draw a firm conclusion that aripiprazole is a safer drug in the treatment of childhood TD.
关键词
阿立哌唑 /
抽动障碍 /
Meta 分析 /
儿童
Key words
Aripiprazole /
Tic disorders /
Meta analysis /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 衣明纪, 孙中运, 冉霓. Tourette 综合征儿童主观生活质量研究[J]. 中国当代儿科杂志, 2011, 13(9): 732-735.
[2] Ghanizadeh A, Mosallaei S. Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome[J]. Brain Dev, 2009, 31(1): 15-19.
[3] Rasmussen C, Soleimani M, Carroll A, et al. Neuropsychological functioning in children with Tourette syndrome (TS)[J]. J Can Acad Child Adolesc Psychiatry, 2009, 18(4): 307-315.
[4] Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome[J]. Neurology, 2003, 60(7): 1130-1135.
[5] Budman CL, Gayer A, Lesser M, et al. An open-label study of the treatment efficacy of olanzapine for Tourette's disorder[J]. J Clin Psychiatry, 2001, 62(4): 290-294.
[6] Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder[J]. Am J Psychiatry, 1997, 154(8): 1057-1062.
[7] Hounie A, De Mathis A, Sampaio AS, et al. Aripiprazole and Tourette syndrome[J]. Rev Bras Psiquiatr, 2004, 26(3): 213.
[8] Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. Available at: http://www.cochrane-handbook.org/: The Cochrane Collaboration, 2011.
[9] 梁月竹, 周福春, 郑毅, 等. 阿立哌唑治疗Tourette 综合征对照研究[J]. 中国神经精神疾病杂志, 2010, 36(2): 111-112.
[10] 刘智胜, 陈燕惠, 钟佑泉, 等. 阿立哌唑治疗Tourette 综合征患儿的多中心对照研究[J]. 中华儿科杂志, 2011, 49(8): 572-576.
[11] 任志斌, 金卫东, 王鹤秋. 阿立哌唑与氟哌啶醇治疗儿童抽动障碍的对照研究[J]. 中国神经精神疾病杂志, 2012, 38(4): 222-224.
[12] 郭芳, 秦鑫, 郭素芹, 等. 阿立哌唑与氟哌啶醇治疗儿童少年抽动障碍的对照研究[J]. 中国健康心理学杂志, 2013, 21(12): 1767-1768.
[13] Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder[J]. J Clin Psychiatry, 2013, 74(8): e772-e780.
[14] Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial[J]. Child Psychiatry Hum Dev, 2013, 45(5): 596-603.
[15] Seo WS, Sung HM, Sea HS, et al. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder[J]. J Child Adolesc Psychopharmacol, 2008, 18(2): 197-205.
[16] Yoo HK, Choi SH, Park S, et al. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders[J]. J Clin Psychiatry, 2007, 68(7): 1088-1093.
[17] 谢琴, 汤珺, 徐杨, 等. 阿立哌唑治疗儿童孤独症的临床观察[J]. 中国当代儿科杂志, 2013, 15(4): 294-297.
[18] Gulisano M, Cali PV, Cavanna AE, et al. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome[J]. Neurol Sci, 2011, 32(6): 1213-1217.
[19] Degrauw RS, Li JZ, Gilbert DL. Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome[J]. Pediatr Neurol, 2009, 41(3): 183-186.
[20] Murphy TK, Mutch PJ, Reid JM, et al. Open label aripiprazole in the treatment of youth with tic disorders[J]. J Child Adolesc Psychopharmacol, 2009, 19(4): 441-447.
[21] Davies L, Stern JS, Agrawal N, et al. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole[J]. Hum Psychopharmacol, 2006, 21(7): 447-453.
[22] 杨自金. 硫必利与氟哌啶醇治疗Tourette 综合征疗效及安全性[J]. 临床儿科杂志, 2012, 30(11): 1051-1053.
[23] Kirschbaum KM, Hiemke C, Schmitt U. Rotarod impairment: catalepsy-like screening test for antipsychotic side effects[J]. Int J Neurosci, 2009, 119(10): 1509-1522.
[24] Lyon GJ, Samar S, Jummani R, et al. Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study[J]. J Child Adolesc Psychopharmacol, 2009, 19(6): 623-633.
基金
省卫计委中医药课题(wzsy201308)。
PDF(2080 KB)
